Should Bleeding Be a Concern in Antiphospholipid Syndrome?

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 Feb 26

PMID 38404938

Authors

Fernanda A Orsi

Affiliations

Soon will be listed here.

References

Cervera R, Khamashta M, Shoenfeld Y, Camps M, Jacobsen S, Kiss E . Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2008; 68(9):1428-32. DOI: 10.1136/ard.2008.093179. View

Stoots S, Lief L, Erkan D . Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2019; 21(10):56. PMC: 7102334. DOI: 10.1007/s11926-019-0852-7. View

Crowther M, Ginsberg J, Julian J, Denburg J, Hirsh J, Douketis J . A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003; 349(12):1133-8. DOI: 10.1056/NEJMoa035241. View

Ames P, Ciampa A, Margaglione M, Scenna G, Iannaccone L, Brancaccio V . Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost. 2005; 93(4):694-9. DOI: 10.1160/TH04-11-0723. View

Bala M, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz M . Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2020; 10:CD012169. PMC: 8094585. DOI: 10.1002/14651858.CD012169.pub3. View

Amigo M, Goycochea-Robles M, Espinosa-Cuervo G, Medina G, Barragan-Garfias J, Vargas A . Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015; 24(9):927-34. DOI: 10.1177/0961203315576858. View

Wittkowsky A, Downing J, Blackburn J, Nutescu E . Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost. 2006; 96(2):137-41. View

Harrington J, Piccini J, Alexander J, Granger C, Patel M . Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. J Am Coll Cardiol. 2023; 81(8):771-779. PMC: 11878670. DOI: 10.1016/j.jacc.2022.11.057. View

Mazodier K, Arnaud L, Mathian A, Costedoat-Chalumeau N, Haroche J, Frances C . Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012; 91(5):251-260. DOI: 10.1097/MD.0b013e31826b971f. View

10.

Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S . Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2022; 81(1):16-30. PMC: 9812926. DOI: 10.1016/j.jacc.2022.10.008. View

11.

Cervera R, Serrano R, Pons-Estel G, Ceberio-Hualde L, Shoenfeld Y, de Ramon E . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014; 74(6):1011-8. DOI: 10.1136/annrheumdis-2013-204838. View

12.

Bazzan M, Vaccarino A, Stella S, Bertero M, Carignola R, Montaruli B . Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev. 2012; 12(8):826-31. DOI: 10.1016/j.autrev.2012.11.007. View

13.

Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N . Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2009; 8(2):237-42. DOI: 10.1111/j.1538-7836.2009.03674.x. View

14.

Zuily S, Cervera R, Foret T, Bertocchi S, Tincani A . Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or antiaggregation always required?. Autoimmun Rev. 2023; 23(1):103417. DOI: 10.1016/j.autrev.2023.103417. View

15.

Tektonidou M, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N . EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78(10):1296-1304. PMC: 11034817. DOI: 10.1136/annrheumdis-2019-215213. View

16.

Ruiz-Irastorza G, Khamashta M, Hunt B, Escudero A, Cuadrado M, Hughes G . Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med. 2002; 162(10):1164-9. DOI: 10.1001/archinte.162.10.1164. View

17.

Shi Y, Zhao J, Jiang H, Huang C, Qi W, Song Y . Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology (Oxford). 2022; 62(1):256-263. DOI: 10.1093/rheumatology/keac264. View

18.

Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G . Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010; 28(21):3516-24. DOI: 10.1200/JCO.2009.27.3524. View

19.

Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J . A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3(5):848-53. DOI: 10.1111/j.1538-7836.2005.01340.x. View